[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100498606":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":29,"locations":10,"responsibleParty":37,"collaborators":39,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":10,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":70,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":10},{"fullName":5,"class":6},"Western University, Canada","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"No pathological signs of rejection",null,"Routine endomyocardial biopsy did no show pathological signs of rejection (0R) based on the International Society for Heart and Lung Transplantation (ISHLT) 2004 acute cellular rejection grading scheme.",[13],"Diagnostic Test: Extra blood samples (5-10 mL) drawn",{"label":15,"type":10,"description":16,"interventionNames":17},"With pathological signs of rejection","Routine endomyocardial biopsy showed pathological signs of rejection (1R, 2R, and 3R) based on the International Society for Heart and Lung Transplantation (ISHLT) 2004 acute cellular rejection grading scheme.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DIAGNOSTIC_TEST","Extra blood samples (5-10 mL) drawn","Extra blood samples will be sent for metabolomics analysis.",[9,15],[25],{"name":26,"affiliation":27,"role":28},"Stuart Smith, MD","Western University","PRINCIPAL_INVESTIGATOR",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Ping Yu Xiong, MD, PhD","CONTACT","613-331-1718","PingYu.Xiong@lhsc.on.ca",{"name":26,"role":32,"phone":10,"phoneExt":10,"email":36},"Stuart.Smith@lhsc.on.ca",{"type":38,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[40,42,45,47],{"name":41,"class":6},"Canadian Cardiovascular Society",{"name":43,"class":44},"Bayer","INDUSTRY",{"name":46,"class":6},"University of Alberta",{"name":48,"class":6},"Queen's University","100498606","cardiac-transplant-metabolomics-with-and-without-rejection-100498606",false,"NCT05772442","Cardiac Transplant Metabolomics With and Without Rejection","Investigating the Metabolomic Profile of Transplanted Heart With and Without Pathological Signs of Rejection","ANTIPARTICLE","Inclusion Criteria:\n\n* All patients with heart transplant undergoing routine endomyocardial biopsy and blood work for transplant rejection screening and workup.\n* Patients or substitute decision makers are able to provide informed consent to agree to participate in this study.\n\nExclusion Criteria:\n\n* Patients or substitute decision makers declined to participate in this study.","ALL","18 Years",{"count":60,"type":61},100,"ESTIMATED","OBSERVATIONAL","Patient who received a heart transplant may develop organ rejection. Currently, an invasive biopsy of the heart needs to be performed to diagnose rejection. The purpose of this research study is to identify novel metabolic biomarkers that can be developed into a blood test that can identify signs of rejection without doing a heart biopsy.",[65],"Heart Transplant Rejection",[67,68,69],"Transplant","Metabolomics","Rejection","NOT_YET_RECRUITING","2024-07-22",{"date":73,"type":74},"2024-07-23","ACTUAL",{"date":76,"type":61},"2024-07",{"date":78,"type":61},"2026-04",{"name":5,"class":6}]